Premium
The proposed initial public offering of Gland Pharma Ltd values the maker of injectable drugs at a premium to locally listed drugmakers but assigns a steep discount to overseas publicly listed companies, a VCCircle analysis shows. The Hyderabad-based company filed for the IPO earlier this month, barely three years after it ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
